Conclusion of Licensing Agreement for Hib Vaccine

Osaka, Japan, January 16, 2012—Mitsubishi Tanabe Pharma Corporation (President and CEO: Michihiro Tsuchiya) and Nuron Biotech (Head Office: Pennsylvania, U.S.) have concluded a licensing agreement for HibTITER®, a vaccine for Haemophilus influenza type B (Hib). Under this agreement, Mitsubishi Tanabe Pharma has acquired from Nuron Biotech exclusive development and sales rights in Japan for HibTITER® as well as for combination vaccines using HibTITER®.

The invasive diseases caused by Hib include bacteremia, meningitis, acute epiglottitis, and purulent arthritis. In particular, pediatric meningitis can be fatal or have long-lasting sequela. Accordingly, the prevention of infection through vaccination is considered to be highly important.

HibTITER® is a liquid form vaccine that combines nontoxic variant of diphtheria toxin with Hib constituents in order to increase its immunogenicity. The vaccine, which has been used in more than 50 countries and regions overseas since the second half of the 1980s, has made a substantial contribution to the prevention of Hib infection. The Company will move forward with development of the vaccine, with the objective of quickly providing the safe and effective Hib vaccine to the medical front lines and people who have not been vaccinated.

Mitsubishi Tanabe Pharma will strive to contribute to society from the viewpoint of disease prevention by aggressively introducing and developing competitive new vaccine products and technologies through the sales foundation that the Company has established.

<Media enquiry>
Corporate Communications Department
Phone: +81 6-6205-5211